Table 1.
The demographics and clinical characteristics of AIDS-related lymphoma (ARL) patients (n = 138).
| Characteristics | DLBCL | BL | Other ARL | Total |
|---|---|---|---|---|
| Sample size, n (%) | 119 (86.2) | 9 (6.5) | 10 (7.3) | 138 (100) |
| Age (range) | 48.69 ± 14.20 (18–77) | 54.22 (41–68) | 49.90 (27–79) | 49.14 ± 14.20 (18–79) |
| Male, n (%) | 97 (81.5) | 6 (66.7) | 10 (100) | 113 (81.9) |
| IPI factor, n (%) | ||||
| Age > 60 years | 30 (25.2) | 3 (33.3) | 4 (40.0) | 37 (26.8) |
| Elevated LDH | 93 (78.2) | 8 (88.9) | 5 (50.0) | 106 (76.8) |
| ECOG PS > 1 | 50 (42.0) | 3 (33.3) | 1 (10.0) | 54 (39.1) |
| Stage III/IV | 54 (45.4) | 4 (44.4) | 3 (30.0) | 61 (44.2) |
| Extranodal sites > 1 | 31 (26.1) | 2 (22.2) | 2 (20.0) | 35 (25.4) |
| IPI, n (%) | ||||
| Low | 40 (33.6) | 4 (44.4) | 6 (60.0) | 50 (36.2) |
| Low-intermediate | 34 (28.6) | 2 (22.2) | 1 (10.0) | 37 (26.8) |
| High-intermediate | 23 (19.3) | 1 (11.1) | 2 (20.0) | 26 (18.8) |
| High | 22 (18.5) | 2 (22.2) | 1 (10.0) | 25 (18.2) |
| E-involvement, n (%) | 70 (58.8) | 5 (55.6) | 6 (60.0) | 81 (58.7) |
| Bulky mass, n (%) | 21 (17.6) | 5 (55.6) | 5 (50.0) | 61 (44.2) |
| B symptoms, n (%) | 51 (42.9) | 1 (11.1) | 0 (0) | 22 (15.9) |
| Prior history of HIV, n (%) | 27 (22.7) | 2 (22.2) | 4 (40.0) | 33 (23.9) |
| LDH (range) | 802.60 ± 1,100.27 (153–9,213) | 524.17 (216–811) | 436.38 (116–1,974) | 757.90 ± 1,039.08 (116–9,213) |
| CD4 T cell (range) | 208.13 ± 168.58 (3–1,089) | 280.78 (73–502) | 322.90 (32–644) | 221.19 ± 172.18 (3–1,089) |
| CD4/CD8 (range) | 0.34 ± 0.24 (0.03–1.47) | 0.56 (0.12–1.15) | 0.50 (0.07–1.69) | 0.37 ± 0.27 (0.03–1.69) |
| PLT (range) | 248.18 ± 120.12 (22–635) | 310.79 (128–587) | 270.30 (22–575) | 253.86 ± 123.55 (22–635) |
| LMR (range) | 3.17 ± 2.58 (0.25–16.50) | 2.36 (1.30–4.25) | 4.21 (1.20–16.50) | 3.19 ± 2.73 (0.25–16.50) |
| PLR (range) | 251.81 ± 316.34 (5.60–3,140.00) | 250.89 ± 131.60 (80–477) | 209.82 ± 110.00 (5.20–383.00) | 248.71 ± 296.85 (5.20–3,140.00) |
| RDW ratio (range) | 0.99 ± 0.18 (0.66–1.73) | 0.99 ± 0.22 (0.82–1.42) | 0.98 ± 0.12 (0.82–1.26) | 0.99 ± 0.18 (0.66–1.73) |
| Hb/RDW (range) | 7.80 ± 2.50 (2.03–12.80) | 7.84 ± 2.45 (4.28–11.05) | 7.46 ± 2.17 (3.75–9.76) | 7.95 ± 2.46 (2.03–12.80) |
| ESR (range) | 52.30 ± 37.03 (2–160) | 74.00 ± 39.96 (25–129) | 54.89 ± 39.20 (6–138) | 54.20 ± 37.53 (2–115) |
| ALB (range) | 34.69 ± 7.71 (6–51) | 35.19 ± 2.325 (33–40) | 32.72 ± 6.16 (20–39) | 34.58 ± 7.376 (6–51) |
| BMI (range) | 21.59 ± 3.48 (12.11–35.88) | 22.87 (18.37–25.97) | 20.27 (17.53–25.10) | 21.58 ± 3.39 (12.11–35.88) |
DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status; E-involvement, extranodal site involvement; PLT, platelet; LMR, lymphocyte to monocyte ratio; PLR, platelet to lymphocyte ratio; RDW ratio, red cell distribution width ratio; Hb/RDW, hemoglobin to red cell distribution width ratio; ESR, erythrocyte sedimentation rate; ALB, albumin; BMI, body max index.